A multidisciplinary team (MDT) approach is necessary in treating metastatic breast cancer in order to provide optimal care. This article, published in JNCCN, reviews the findings of an educational needs assessment of the multidisciplinary breast cancer management team.
Data support use of bendamustine for patients treated with several lines of therapy, but whether this drug should be used in the first line is open to question.
Several promising drugs have been approved for the treatment of bladder cancer within the phase year, but combination therapies may be still more effective.
Long-term follow-up data from randomized trials on Hodgkin lymphoma support current risk-adapted therapeutic approaches for early-stage disease.
This PD-1 inhibitor is effective for treating melanoma, though it can be highly toxic and there is a lack of biomarkers for predicting a response.
Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- In Focus: Atezolizumab for Non-small Cell Lung Cancer
- FDA Warns 14 Companies To Stop Selling Illegal Cancer Treatments
- ASCO Releases Opinion on Hormonal Therapy for Castrate-resistant Prostate Cancer
- Pembrolizumab for Advanced Melanoma: Efficacy and Toxicity
- Bladder Cancer: Immunotherapies, Combination Therapies, and Current Research